Serum Institute of India has requested the inclusion of its Covid vaccine Covovax as a heterologous booster dosage for adults in the CoWIN portal, according to official sources on Wednesday.
According to them, the letter was composed by Prakash Kumar Singh, Director of Government and Regulatory Affairs at Serum Institute of India (SII).
The National Technical Advisory Group on Immunisation (NTAGI) is anticipated to have a meeting in the near future to make a decision.
On January 16, the Drug Controller General of India (DCGI) issued marketing authorization for Covovax as a heterologous booster dosage for people who have received two doses of Covishield or Covaxin.
The suggestion of the subject expert committee (SEC) of the Central Drugs Standard Control Organisation led to its approval.
Covovax was approved by the DCGI for restricted use in emergency cases in adults on December 28, 2021, in adolescents aged 12 to 17 on March 9, 2022, and in children aged seven to eleven on June 28, 2018 under certain conditions.
Covovax is produced by the transfer of technology from Novavax.
It has been awarded conditional marketing permission by the European Medicines Agency and emergency use listing by the World Health Organization (WHO) on December 17, 2021.
The US-based vaccine manufacturer Novavax Inc. announced a licence deal with the SII for developing and commercialising their COVID-19 vaccine candidate, NVX-CoV2373, in India and low- and middle-income countries in August 2020.